The vessel: an in vitro assay
Sean B. Carroll's team examined four conserved metalloproteinase inhibitors derived from the protein Fetuin-A in rattlesnake serum. Specific combinations are reported to complement one another's activities, to suffice to fully neutralise rattlesnake venom lethality, and to show approximately ten times greater potency than commercial antivenom. The combinations gave broad protection against venoms from several viper species. The measurement was made in vitro; efficacy and safety in humans were not demonstrated.[1]
That potency figure is the first step on the road to a patient outcome. The tissue a patient loses is decided in the minutes after venom enters the blood; in a laboratory vessel, venom and inhibitor usually meet at the same moment. The published material shows the strength of the binding; timing is something a study at this stage does not undertake to measure.[1]
The denominator: one toxin family
The work targets only toxins in the metalloproteinase family. Viper venom is a mixture doing different jobs, from tissue destruction to disrupted clotting, and other families would need comparable development. The tenfold figure was measured against one slice of the venom.[1]
Even so, what makes this work most interesting sits in the source of the inhibitor. An inhibitor produced recombinantly removes a manufacturing chain that depends on immunising animals; consistency of product and reliability of supply may be a more durable gain than the potency figure. Against that, there is a more prosaic account of the same result: the commercial antivenom used as the comparator may already be relatively weak against this particular toxin family, so the tenfold may be measuring the old product's shortfall on a narrow slice.[1]
What the next measurement should be
The honest sentence at this stage is that it works in the vessel. The next step is animal work with a declared dose and a prespecified survival endpoint, after which immune response and residence time in the body have to be measured alongside potency. The person who meets a rattlesnake bite is usually rural and far from a hospital; the number that matters for them is what a dose given in the first hour after the bite actually does.[1]